Aravive opens enrollment in phase Ib/II study of AVB-S6-500 in clear cell renal cell carcinoma Dec. 15, 2020
Novel potent PI3Kdelta inhibitors that target two different mechanisms of isoform selectivity Dec. 14, 2020
AbbVie conducts phase Ib study of eftozanermin alfa in relapsed or refractory multiple myeloma Dec. 14, 2020
Mutant EGFR inhibitors presented by Jiangsu Hansoh Pharmaceutical Group, Shanghai Hansoh Biomedical Dec. 11, 2020
RSS